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Abstract
Low-grade gliomas (LGGs) account for about a third of all brain tumours in children. We conducted a detailed
study of DNA methylation and gene expression to improve our understanding of the biology of pilocytic and
diffuse astrocytomas. Pilocytic astrocytomas were found to have a distinctive signature at 315 CpG sites, of which
312 were hypomethylated and 3 were hypermethylated. Genomic analysis revealed that 182 of these sites are
within annotated enhancers. The signature was not present in diffuse astrocytomas, or in published profiles of other
brain tumours and normal brain tissue. The AP-1 transcription factor was predicted to bind within 200 bp of a
subset of the 315 differentially methylated CpG sites; the AP-1 factors, FOS and FOSL1 were found to be
up-regulated in pilocytic astrocytomas. We also analysed splice variants of the AP-1 target gene, CCND1, which
encodes cell cycle regulator cyclin D1. CCND1a was found to be highly expressed in both pilocytic and diffuse
astrocytomas, but diffuse astrocytomas have far higher expression of the oncogenic variant, CCND1b. These findings
highlight novel genetic and epigenetic differences between pilocytic and diffuse astrocytoma, in addition to
well-described alterations involving BRAF, MYB and FGFR1.
Keywords: Diffuse astrocytomas, MAPK pathway, AP-1 targets, FOS, Cyclin D1, Enhancers
Introduction
Pilocytic astrocytomas (WHO grade I) constitute the
majority of paediatric low-grade gliomas (LGGs). They
usually arise in the cerebellum but are also found in
other sites such as the optic pathways and cerebral
hemispheres. Pilocytic astrocytomas typically contain a
BRAF fusion but occasionally a BRAFV600E mutation,
RAF1 fusion, intragenic duplication of FGFR1, or other
rarer alterations are present [21, 65]. Diffuse astrocyto-
mas (WHO grade II) usually occur in the cerebral hemi-
spheres, but are also found in the brainstem and spinal
cord. Various genetic alterations have been identified in
diffuse astrocytomas, including BRAF V600E mutations,
intragenic duplication of FGFR1, structural alterations of
the MYB oncogene and gene fusions involving FGFR1,
FGFR3, MYB and MYBL1 [65]. Virtually all the key
genetic alterations in pilocytic and diffuse astrocytomas
give rise to constitutive activation of the ERK/MAPK
pathway [10, 20, 43, 65], but these tumour types exhibit
significant biological and clinical heterogeneity. While
pilocytic astrocytomas are well-circumscribed, non-invasive
tumours, diffuse astrocytomas invade surrounding tissue
and thus have a worse outcome. It is therefore likely that
other factors, such as epigenetics and regulating
RNAs, as well as the cell of origin and the developing
brain environment, influence the divergent phenotypic
behaviour [1, 22]. DNA methylation is altered in both can-
cer [14] and during brain development [30]. However, its
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contribution to paediatric low-grade glioma tumorigenesis
has not been extensively studied.
We have conducted a comprehensive analysis of DNA
methylation together with gene expression in pilocytic
and diffuse astrocytomas from two independent tumour
sets (test set n = 27 and validation set n = 59) using the
Illumina HumanMethylation450 BeadChip (450K). Com-
parison between the tumour types and normal brain
controls identified tumour-specific differences in the
DNA methylation patterns. We identified a hypomethy-
lation signature specific to pilocytic astrocytomas,
characterised by differentially methylated CpG sites
predominantly in annotated enhancers. Additionally, we
were able to show that the AP-1 transcription factor
complex is predicted to bind at a number of the differ-
entially methylated CpG sites. The AP-1 complex is
formed by dimerisation of the FOS and JUN family of
transcription factors and is activated by the MAPK path-
way [9, 40]. In this study, the FOS family of transcription
factors was found to be up-regulated in pilocytic astro-
cytomas. The AP-1 gene target CCND1a was also up-
regulated in both pilocytic and diffuse astrocytomas,
with higher levels of the oncogenic CCND1b transcript
expressed in the diffuse astrocytomas.
Materials and methods
Low-grade astrocytoma cohort
The test tumour set consisted of 17 pilocytic astrocytomas
and 10 diffuse astrocytomas (Additional file 1: Table S1).
Validation tumour set 1 consisted of 23 pilocytic astrocy-
tomas and 8 diffuse astrocytomas and validation tumour
set 2 consisted of 45 pilocytic astrocytomas; 6 diffuse as-
trocytomas and 8 oligoastrocytomas (Additional file 1:
Table S1). All tumours were obtained as surgical speci-
mens. Ages of the patients at diagnosis ranged from 3 to
20 years. Access to tumours and linked clinical data was
given in accordance with Institutional Review Board and
MREC regulations: St Jude Children’s Research Hospital
(USA) XPD07-107/IRB; Newcastle (UK) REC ref No
2002/112; Blizard Institute (UK) ICMS/PR/09/77. The
controls were human neural progenitor cells (ReN VM
cell-line), adult brain, foetal cerebellum, foetal frontal lobe
and foetal brain (normal brain, BioChain).
Infinium HumanMethylation450 BeadChip processing
Sample DNA (1 μg) was bisulphite-converted using the
EZ DNA methylation kit (Zymo Research) and analysed
using the Infinium HumanMethylation450 BeadChip (Illu-
mina Inc.). The samples and 450K BeadChips were proc-
essed according to the manufacturer’s protocol at Barts
and The London Genome Centre, UK. Pre-processing of
the 450K dataset was performed using Genome studio
software v.2011.1 (Illumina Inc.). Quality control of bisul-
phite conversion was performed by calculating the ratio of
unmethylated probe to methylated probe. Samples that
had incomplete conversion (a ratio >0.2) were removed.
Methylation status for each probe is given as a Beta
value (β-value). The β-value is the ratio of the meth-
ylated probe intensity and the overall intensity (sum
of the methylated and unmethylated probe inten-
sities). Pre-processing of the data was then performed
using R (version 2.15.0). Peak correction was per-
formed [39] and probes that contained a minor allele
frequency of >5 % within 50 bp of the target site
were removed [59]. The Illumina annotation [3] and
an enhanced annotation ([42] were added to the
peak-corrected datasets (Additional file 2: Table S2).
We excluded probes located on the X- and Y- chro-
mosomes from further analysis. The dataset generated
in this study has been deposited in the Gene Expres-
sion Omnibus (GEO) under accession GSE77241.
Differential methylation analysis
Differential methylation analysis was performed using
the MethLAB R-based programme [23] (R version
2.15.0). The programme enables us to identify signifi-
cantly differentially methylated CpGs from the corrected
β-values. The linear model with the factor of interest
(tumour type – pilocytic, diffuse, control) was computed,
with other varying factors: bead chip number (1–5),
BRAF status (fusion, V600E mutation, WT), sample lo-
cation (infratentorial/supratentorial), age group (foetal/
HNSC, <3 years, > = 3 years, >16 years) and gender
included. A class covariance and FDR correction
(Benjamini-Hochberg) were performed. In this ana-
lysis the dependent variable is the β-value for each
probe, and the independent variables are phenotypic
factors such as tumour type. Further details for each
analysis are shown in Additional file 3: Supplementary
Methods. The differentially methylated CpG sites of
interest had a differential change (delta Beta value) of
≥0.3 with FDR-corrected p-value <0.05. A list of the com-
parisons performed is shown in Additional file 4: Table S3.
Expression analysis
Expression analysis was performed on 8 pilocytic astro-
cytomas and 10 diffuse astrocytomas from the test
tumour set, using Affymetrix Human U133_plus2 arrays
[65]. The data were analysed using GeneSpring software
(Agilent). Analysis was performed using the RMM
model, with median baseline correction and data log2
transformation (Additional file 5: Table S4). For differen-
tial expression analysis, the tumour groups were aver-
aged and the difference between the two groups was
taken. Differentially expressed genes had a fold change
of >2(differential log2 transformed values >1).
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Pathway analysis and transcription factor binding motif
analysis
Ingenuity pathway analysis (Ingenuity Systems Inc.) was
used to identify key signalling and biological pathways
from the genes identified as differentially methylated.
For the top biological functions and canonical pathways,
the log p-value was calculated by Fisher exact Test, with
a threshold set at a p-value <0.05. The TFsearch software
which utilises the TRANSFAC database [15] was used to
predict transcription factor binding sites 100 bp either
side of the differentially methylated CpG sites.
Marmal-aid database analysis
To analyse the differentially methylated CpG sites in
published profiles for other brain tumours, we used the
Marmal-aid database [33]. Hierarchical clustering and
heatmaps were produced using the R-programme fastclus-
ter on R version 2.15.0. The database was used to assess
450K methylation datasets for adult low-grade gliomas
(TCGA), adult and paediatric glioblastomas (GSE36278
[51]) and pilocytic astrocytomas (GSE41826, [27]). Heat-
maps were also produced for validation tumour set 2 and
for medulloblastomas [45].
Bisulphite converted DNA and PCR for pyrosequencing
Quantitative DNA methylation analysis was performed
at 7 selected genes using pyrosequencing in the test
tumour set and in validation set 2 (Additional file 6:
Table S5). Amplification of 50 ng of bisulphite-converted
DNA was performed using 0.03 U/μl Platinum Taq poly-
merase (Life Technologies), 1 x PCR buffer, 3 mM MgCl2,
0.8 mM dNTP, 200 nM forward primer, 200 nM reverse
primer, 0.5 M Betaine (Sigma Aldrich) and nuclease-free
water. PCR cycling at 92 °C for 10 mins, then 44 cycles at
92 °C for 30 s, 50 °C for 1 min and 72 °C for 40 s, with a
final extension step of 72 °C for 5 mins. Strand separation
and pyrosequencing were performed at Barts and The
London Genome Centre, UK.
Methylation analysis of 11 CpG sites in the CCND1
gene and analysis of the G870A SNP were performed by
amplification of 50 ng of bisulphite converted DNA as
stated above. The primers amplified a region of 362 bp
encompassing exon 4 and the intron boundary (Primers,
forward 5′-GTTTTAGATGTGAAGTTTATTTTTAA-3′
and reverse 5′-TATAAAAACCTCCCAACCAATC-3′).
The amplicons were Sanger sequenced in both directions
to obtain CpG and SNP status.
CCND1 qPCR assay
Conversion of 500 ng of RNA into cDNA was performed
using the SuperScript II reverse transcriptase (Life Tech-
nologies) following the manufacturer’s protocol. Amplifi-
cation was performed in duplicate with a technical
replicate (n = 2 for cDNA conversion). PCR reactions
consisted of SYBR® Green Jumpstart Taq ReadyMix TM
(1x; Sigma‐Aldrich), forward and reverse primers
(10 μM each), made up to 20 μl with nuclease-free
water. Primer sequences for CCND1a (forward – 5′-
CTCTCCAGAGTGATCAAGTGTGACCC-3′, reverse –
5′-TGTGCAAGCCAGGTCCACC-3′;[7]; CCND1b
(forward- 5′-AACAGATCATCCGCAAACACGC-3′,
reverse – 5′-CATGAGTCCTTCCACGATACC-3′; [5];
GAPDH (forward- 5′‐GTGAACCATGAGAAGTATGA
CAAC‐3′, reverse- 5′‐ CATGAGTCCTTCCACGATACC‐
3′) and TBP (forward - 5′‐CACGAACCACGGCACT
GATT‐3′, reverse 5′‐TTTTCTTGCTGCCAGTCTG
GAC‐3′). The cycling conditions were 50 °C for 2 min,
95 °C for 10 min, followed by cycles of 95 °C for 15 s,
60 °C for 40 s and 72 °C for 40 s, for 40 cycles. A dissoci-
ation stage of 95 °C for 15 s, 60 °C for 1 min, 95 °C for 15 s
and 60 °C for 15 s, was included. PCRs were performed on
the 7500 Real-Time PCR system (Applied Biosystems®).
The fold change was calculated using the ΔΔCT rela-
tive quantification method [32].
MicroRNA Taqman assays
Conversion of 10 ng of RNA into cDNA was performed
using the Taqman® MicroRNA Reverse Transcription
(RT) kit (Life Technologies) following the manufacturer’s
protocol. RT-reaction conditions were 1 x Reverse Tran-
scription buffer, 1 mM dNTP, 3.3 U/μl MultiScribe™
Reverse Transcriptase, 0.25 U/μl RNase Inhibitor, 10 ng
RNA sample, 1 x RT microRNA-specific primer and
nuclease-free water. RT-reaction was incubated at 16 °C
for 30 mins, 42 °C for 30 mins and 85 °C for 5 mins.
TaqMan® miRNA assays (Life Technologies) were used
to analyse expression levels of microRNAs miR-21* and
miR-155, with all samples normalised to control micro-
RNA, miR-423-3p. PCR reaction conditions were 1 ng/μl
RT-product, 1x Taqman® Universal PCR master mix II
(no UNG), 1 x Taqman® probe and nuclease-free water.
PCR cycling conditions were 95 °C for 10 mins, followed
by 40 cycles of 95 °C for 15 s and 60 °C for 1 min. Fold
changes were calculated relative to the average expression
in adult and foetal cerebellum and frontal lobe (n = 7).
Results
Identification of a hypomethylation signature specific to
pilocytic astrocytomas
DNA methylation profiles were identified for the test
tumour set (11 infratentorial pilocytic astrocytomas; 6
supratentorial pilocytic astrocytomas and 10 diffuse
astrocytomas), 4 normal brain control samples and the
ReN VM neural stem cell-line using the Illumina Infinium
HumanMethylation450 BeadChip [3, 8]. Profiles were
then subjected to extensive comparisons, as summarised
in Additional file 4: Table S3.
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We first conducted a three-way comparison of pilocy-
tic astrocytomas, diffuse astrocytomas and normal brain
and ReN VM neural stem cell-line controls (Fig. 1a;
Additional file 4: Table S3, Panel A and Additional file 7:
Table S6). Differential methylation was identified at 958
CpG sites in pilocytic astrocytomas vs. controls and 352
sites in diffuse astrocytomas vs. controls (FDR-corrected
p-value <0.05 and Δβ >0.3). Of the 993 differentially
methylated CpG sites found in either of these comparisons,
317 sites were common to both comparisons (Fig. 1b, c).
Ingenuity Pathway Analysis of genes associated with the
993 sites is shown in Additional file 8: Table S7. We also
performed differential methylation analysis comparing the
genetic alteration status, specifically looking at BRAF fusion
status (n = 12) and then grouped BRAF fusion and
BRAFV600E status (n = 17) of the tumours (Additional file 3:
Supplementary Methods). No significant CpG sites were
identified.
Hierarchical cluster analysis of the samples at the
993 CpG sites showed clustering of all the pilocytic
astrocytomas except two supratentorial tumours, PA1
and PA4, which clustered with the diffuse astrocyto-
mas and neural stem cell sample (Fig. 1d). Whilst
PA4 contained the BRAF fusion, PA1 contained the
STGAL1-WHSC1 fusion together with further com-
plex rearrangements as shown by whole genome se-
quencing [65], which may account for this tumour
clustering with the diffuse astrocytomas. We then
examined the locations of the 993 sites relative to
CpG islands and to different regions of the 536 genes
associated with 671 of these sites (Fig. 1e,f,g,h,i).
Unlike other cancers where changes are mainly iden-
tified in the shores [19], the majority of the differen-
tially methylated CpGs were found to be located in
open sea regions. The sites associated with genes
were mostly located within the gene body and regions
up- or down-stream of the gene, rather than at
transcription start sites. As the unsupervised cluster-
ing of the total 450K dataset could not distinguish
between the two tumour groups we compared pilocytic
Fig. 1 Features of 993 differentially methylated CpG sites in pilocytic and diffuse astrocytomas compared to controls. a Three-way comparison of
differentially methylated sites in pilocytic astrocytomas, diffuse astrocytomas and control brain tissue. b Numbers of common and unique differentially
methylated sites in pilocytic and diffuse astrocytomas. c Percentages of hypermethylated (dark grey) and hypomethylated (light grey) differentially
methylated sites in pilocytic and diffuse astrocytomas compared to normal controls. d Hierarchical clustered heatmap showing 993 differentially
methylated sites. Methylation beta values are represented in shades of blue = 0 (methylated) to yellow = 1 (unmethylated). Tumour type,
tumour location, age, sex, KIAA1549-BRAF fusion status, and genomic mutations are shown [65]. FFL, Foetal frontal lobe; Foetal, foetal brain;
FCB, foetal cerebellum; Adult, adult brain, NSC, neural stem cells; PA, pilocytic astrocytomas; DA, diffuse astrocytomas; ND, not determined. e Diagrammatic
representation of the Illumina 450K annotated CpG features in relation to intragenic locations, and f in relation to UCSC Genome Browser-annotated CpG
islands. g Distribution of the differentially methylated CpG sites across the annotated gene regions. TSS1500, 201-1500 bp upstream of transcription start
(TSS); TSS200, up to 200 bp upstream of the TSS; UTR, untranslated region. h Distribution of the differentially methylated CpG sites in relation to CpG
islands. i Distribution of the differentially methylated CpG sites in relation to CpG density [42]. HC, high CpG density; IC, intermediate CpG density; IC shore,
intermediate CpG density shore; LC, low CpG density
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astrocytomas vs. diffuse astrocytomas. Only 315 differen-
tially methylated sites were identified after exclusion of
differences between the matched brain locations of the
tumours. The majority of these sites are hypomethylated
in pilocytic astrocytomas and the distinctive signature was
not present in normal brain controls (Fig. 2). The lack of
CpG sites which are differentially methylated in diffuse
astrocytomas could be due to the genetic heterogeneity
within the diffuse astrocytromas but may also be due to
normal brain admixture in some of the tumour samples,
which can be more of a feature of diffuse astrocytomas
than the well-circumscribed pilocytic astrocytomas.
We confirmed our findings by showing good correlation
between the 450K BeadChip values with pyrosequencing
methylation values for 5 CpG sites (Additional file 3: Figure
S1). We also validated the methylation status at selected
genes using pyrosequencing on the test tumour set and
validation tumour set 1. The genes chosen for validation
showed differential methylation between pilocytic astrocy-
tomas and normal brain controls or between pilocytic
astrocytomas and diffuse astrocytomas. The genes of
interest were the RAS-RAF inhibitor, SPRED2 (Additional
file 3: Figure S2; [60, 61]); miR-21, an AP-1 target which is
involved in gliomagenesis (Additional file 3: Figures S3 and
S5; [11, 55, 56]); miR-155, which is involved in inflamma-
tion and the mTOR pathway (Additional file 3: Figures S4
and S5 [37, 62]), and two genes involved in drug resistance,
ABCC3 (Additional file 3: Figure S6 [4, 67]) and SELENBP1
(Additional file 3: Figure S7; [18, 47, 66]).
The 315 CpG sites which were predominately hypo-
methylated in pilocytic astrocytomas were validated in a
second set of paediatric low-grade astrocytomas, which
were analysed independently with the Illumina 450K system
(validation set 2, n = 59; Additional file 3: Figure S8). Add-
itionally, the differences were confirmed to be irrespective
of tumour location, as the hypomethylation signature was
Fig. 2 Differentially methylated CpG sites in pilocytic and diffuse astrocytomas: comparison with normal brain tissue, and characteristics. a Hierarchical
clustering of pilocytic and diffuse astrocytomas, normal controls, and additional brain samples. Test tumours: PA, pilocytic astrocytomas; DA, diffuse
astrocytomas. Controls: FFL, Foetal frontal lobe; FB, foetal brain; FCB, foetal cerebellum; AB, adult brain, ACB, adult cerebellum; NSC, neural stem cells.
Additional datasets from normal brain tissue are derived from GEO Accession GSE41826: 4782 N/4782G, 165 N/165G, 1230 N/1230G, 1497 N/1497G,
neuronal or glial component of cerebral cortex; MIX1 and MIX7, mix of glial and neuronal components of cerebral cortex [12]. The overwhelming
majority of hypomethylated sites are specific to pilocytic astrocytomas. Two main branches emerge, one of which contains most of the pilocytic
astrocytomas and the other contains the normal brain controls and diffuse astrocytomas, which grouped with glial component of the cerebral cortex.
Foetal brain regions and adult cerebellum clustered together. A subset of astrocytomas grouped with the neural stem cells. Columns represent
individual samples; rows represent 450K CpG probes. As four values were missing in the normal brain dataset only 311/315 sites are shown.
Methylation beta values are represented in shades of yellow = 0 (unmethylated) to blue = 1 (methylated). b Validation of the hypomethylated
signature in a larger published set of pilocytic astrocytomas (PA validation set 2; n = 61; GSE44684 [27]). The hypomethylation signature was identified
in both infratentorial and supratentorial pilocytic astrocytomas. BRAF-fusions were present in 51/62 samples in this tumour set. Only 287/315 sites were
present in the published data set. Tumour samples on the left of the red line are the test tumours in the current study, samples on the right of the line
are validation set. Columns represent individual samples; rows 450K CpG probes. c Distribution of the 315 differentially methylated CpG sites across the
Illumina 450K-annotated location CpG features. TSS1500, 201-1500 bp upstream of transcription start (TSS); TSS200, up to 200 bp upstream of the TSS;
UTR, untranslated region d Distribution of the 315 differentially methylated sites in regions of high, intermediate and low CpG density [42]. HC, high
CpG density; IC, intermediate CpG density; IC shore, intermediate CpG density shore; LC, low CpG density
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Fig. 3 (See legend on next page.)
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also present in pilocytic astrocytomas located in the brain
stem, diencephalon and optic nerve (Fig. 2b; published pilo-
cytic astrocytoma validation set 3, n = 61; GSE44684 [27]).
To confirm that the distinctive signature was specific for
pilocytic astrocytomas, the 315 sites were then examined in
published findings of DNA methylation in other brain tu-
mours, using the Marmal-aid database [33]. The hypome-
thylation signature was not present in other low-grade
astrocytomas (adult gliomas –TCGA), paediatric and adult
glioblastomas (GSE36278 [51]), medulloblastomas [45] or
ependymomas (GSE45353 [35]; Additional file 3: Figures S9
and S10; Additional file 9: Table S8). The signature was also
absent in tissue from foetal brain tissue (GSE58885 [49];
Additional file 3: Figure S11).
We then examined the genomic features of the 315
differentially methylated sites and found that 235 sites
(75 %) were in regions of low CpG density, and 182 sites
(58 %) were in enhancer regions (Illumina annotated,
statistically significant - Chi-square p-value <0.01; 149/182
sites were in regions of low CpG density; (Additional file
10: Table S9). Ingenuity Pathway Analysis of the 185 genes
that were directly linked to 217/315 sites showed signifi-
cant association with Cancer (Additional file 11: Table S10).
The remaining 98 CpG sites were located in intergenic
regions. We assigned 82 genes to these intergenic sites
by finding the closest transcription start sites (TSS)
(Additional file 10: Table S9). Differential gene expression
of ≥ 2-fold between pilocytic and diffuse astrocytomas was
found for 56/267 genes (185 annotated genes and 82
closest TSS-assigned genes; Additional file 12: Table S11).
Correlation was then assessed between gene expres-
sion and methylation for the 70 differentially methylated
CpG sites in the 56 genes (Additional file 13: Table S12).
When the CpG site was located within the gene body or
intergenic regions, correlation was also examined for a
CpG site within the promoter region. Significant correl-
ation was identified in 36 genes for 47 CpG sites, 12 of
which were located in promoter regions and 35 were in
the gene body or in the intergenic regions (Fig. 3).
Examples of the correlations are shown in Fig. 4. The
functions of the 36 genes are presented in Table 1 and
Additional file 14: Table S13. The genes identified are
involved in cell morphology, cell signalling and some are
downstream targets of the MAPK pathway.
Identification of AP-1 binding sites at the differentially
methylated CpG sites and up-regulation of AP-1 targets
in pilocytic astrocytomas
Hypomethylation at enhancer regions is reported to be
tissue-specific and may reflect the presence of specific
transcription factors at these sites [16, 50]. We therefore
examined the genomic regions around the 315 differen-
tially methylated CpG sites to identify transcription factor
binding motifs [15]. The most frequently identified tran-
scription factor binding sites were AP-1 and AML1α. Both
AP-1 and AML1α were up-regulated in pilocytic astrocy-
tomas (Additional file 15: Table S14). The AP-1 transcrip-
tion factors FOS and FOSL1 were found to be significantly
up-regulated in the pilocytic astrocytomas compared to
diffuse astrocytomas and normal brain controls (Fig. 5;
Additional file 3: Figure S12). Further analysis also re-
vealed that a subset of published and predicted targets of
AP-1 is up-regulated in pilocytic astrocytomas, including
the cyclin D1 gene CCND1 (Additional file 16: Table S15).
CCND1 regulates the cell cycle, and encodes two splice
variants, CCND1a and an oncogenic form, CCND1b
(Fig. 6a). While expression of both CCND1a, and CCND1b
was higher in tumours than normal brain controls, diffuse
astrocytomas expressed far more oncogenic CCND1b than
pilocytic astrocytomas (Fig. 6b). Interestingly, the SNP
rs9344 (G870A), which is located within a CpG site at the
splice site at exon 4 - intron 4, is abolished in the presence
of the A-allele and has been reported to be associated with
expression of CCND1b [7, 48] (Fig. 6c). We then examined
DNA methylation at the splice site of the exon 4 – intron 4
boundary, which was not covered by the Infinium Human-
Methylation450 BeadChip. A 372 bp region covering all of
exon 4 and 224 bp of intron 4, including the SNP, was
Sanger-sequenced to identify the qualitative methylation
status of the 11 CpG sites located within this region
(Additional file 3: Figure S13). Differential methylation was
identified at the adjacent CpG site to the SNP showing
hypomethylation in pilocytic astrocytomas. This finding was
confirmed by pyrosequencing. Although differential methy-
lation was identified for these tumours, no significant correl-
ation was identified between methylation and CCND1b
expression (Additional file 3: Figure S13). Additionally, no
correlation was identified between allele status of the SNP
and CCND1b expression (Additional file 3: Figure S13).
(See figure on previous page.)
Fig. 3 Correlation between gene expression and the differentially methylated CpG sites for genes showing ≥2 fold difference in expression
between pilocytic and diffuse astrocytomas. a Correlation coefficients for differential CpG sites located within the promoter region. CpG sites that
showed significant correlation with gene expression are highlighted (** p-value <0.01, * p-value <0.05). b Methylation status (beta values) for the
pilocytic and diffuse astrocytomas for the promoter differential CpG site. c Correlation coefficients for differential CpG sites located within the gene
body and intergenic regions that showed significant correlation with gene expression (p-value <0.05). Genes showing the greatest statistical
significance are placed at the top. Correlation coefficients for corresponding promoter CpG sites, and the methylation status (Beta values) for the
promoter CpG site and the differentially methylated CpG site are also shown. Pilocytic astrocytomas (n = 8, 4 supratentorial and 4 infratentorial
tumours), Diffuse astrocytomas (n = 10). Error bars show the standard deviation for the average beta value for each tumour group
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Fig. 4 (See legend on next page.)
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Comparison of low-grade astrocytomas with normal brain
tissue from tumour matched locations
We then examined DNA methylation profiles for infraten-
torial and supratentorial pilocytic astrocytomas and diffuse
astrocytomas, as separate groups, with control tissue appro-
priate to their respective locations. Published control
profiles for cerebellum and cerebral cortex were included
[12, 27]. Comparison of infratentorial pilocytic astrocyto-
mas with all cerebellar controls identified 11,671 differen-
tially methylated CpG sites (FDR-corrected p-value <0.05,
Δβ > 0.3) (Additional file 17: Table S16; Additional file 4:
Table S3, Panel B). The large number of differentially
methylated CpG sites could be due to normal cerebellum
having a greater neuronal component (3:1 neuronal to non-
neuronal) than the tumours, which would contain mainly
glial cells. Of the 11,671 differentially methylated sites, 8,108
were associated with 3,925 genes (Additional file 17: Table
S16). The distribution of these differentially methylated
CpG sites across gene regions is shown in Additional file 3:
Figure S14. Analysis of gene expression profiles in these tu-
mours showed that 146 (3.3 %) of the genes had ≥2 fold dif-
ferences compared to all the cerebellum controls as a single
group. Ingenuity Pathway Analysis revealed that the top five
pathways associated with the 146 deregulated genes are
cellular movement, cancer, amino acid metabolism, cellular
growth and proliferation, with the functions including neuri-
togenesis and neuron development (Additional file 18: Table
S17). This was in agreement with previous findings [27].
Comparison of supratentorial pilocytic astrocytomas and
diffuse astrocytomas with all cerebral cortex controls identi-
fied 382 and 58 CpG sites (43 sites in common), respectively,
that were differentially methylated (Additional file 4: Table S3,
Panel C and D; Additional file 19: Table S18 and Additional
file 20: Table S19). Comparison of supratentorial pilocytic as-
trocytomas and diffuse astrocytomas with glial and neuronal
components of cerebral cortex [12] showed that the tumours
were more closely related to the glial component, as expected
(Additional file 19: Table S18 and Additional file 20: Table
S19, Additional file 4: Table S3, Panel E; Additional file 9:
Table S8). Hierarchical clustering of the 397 CpG sites
clustered all the controls, with two major branches for the
majority of the pilocytic astrocytomas and diffuse astrocyto-
mas (Additional file 3: Figure S15). Of the genes that have
differential methylation, expression of the down-regulated
genes in the pilocytic astrocytomas are involved in neuronal
differentiation and brain function, with the up-regulated genes
involved in the inflammatory response, apoptosis, metabolic
processes andMAPK pathway (Additional file 19: Table S18).
Finally, comparison of infratentorial and supratentorial
pilocytic astrocytomas identified only 72 differentially
methylated sites, most of which were relatively hypomethy-
lated in infratentorial tumours (Additional file 4: Table S3,
Panel F; Additional file 21: Table S20). All 72 CpG sites
were also hypomethylated in the infratentorial pilocytic
astrocytomas compared to the diffuse astrocytomas.
CpG sites included in this group were associated
(See figure on previous page.)
Fig. 4 Intragenic CpG sites showing negative correlation with gene expression when promoter region is hypomethylated. The 6 genes all have
differentially methylated CpG within the first intron, which show greater negative correlation (with FDR corrected p-values <0.05) than a CpG site
within the TSS200. a AIM1 (218568_at, cg14426428 r = -0.92, p-value <6.04E-0.6, cg18405900 r= -0.41, p-value <0.52). b IGF1R (203627_at, cg26577252
r = -0.81, p-value <0.00008, cg20479870 r = 0.08, p-value <0.94). c OPCML (206215_at, cg14872762 r = -0.82, p-value <0.0007, cg23236270 r = -0.66, p-value
<0.122). d ABCC3 (209641_at, cg25928474 r = -0.77, p-value <0.002, cg20633883 r = -0.34, p-value <0.68). (Affymetrix expression probe, differential CpG
probe, TSS200 probe, correlation coefficients for each CpG probe against expression probes (r-value) and significance (FDR corrected B-H p-values) are
shown, respectively. The gene region is shown with CpG probes, for the whole gene, represented by numbers. The heatmaps show the beta values for
the CpG sites for 8 pilocytic and 10 diffuse astrocytomas that have expression data (beta values yellow, unmethylated 0 – blue, methylated 1). The CpGs
are numbered as shown in the gene region. Blue asterisk - enhancer CpG, red asterisk – TSS200 CpG. In the correlation graphs promoter (TSS200) probe
values are shown as red squares and the differential CpG values are shown as blue diamonds
Table 1 Functions of genes which show a significant correlation
between DNA methylation and gene expression. The majority of
genes were hypomethylated and up-regulated in pilocytic
astrocytomas compared to diffuse astrocytomas, except the
three genes highlighted in bold
MAPK pathway and downstream targets:
DUSP5
FOS
MIR21
CDK6
Tumour suppressors:
AIM1
OPCML
MCC
IRX1
Multidrug resistance:
ABCC3
Inflammation:
SOCS3
IL6ST
CD59
Other:
FAM89A
FAM167A
PRSS23
WSCD1
STAMBPL1
TMEM169
Receptors and channels:
HRH1
LDLRAD3
RARRES1
IGF1R
GRIA4
CHRM3
TRPM8
KCND2
GJA1
Cell morphology, motility
and interactions:
MDGA2
TM4SF1
TMEM132C
IGSF9B
KIRREL3
LEPREL1
TMEM49
COTL1
PTPRE
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with 28 genes, including NR2E1 and EMX2OS, which had 9
and 3 differentially methylated sites, respectively (Additional
file 3: Figure S16 and Additional file 3: Figure S17). A fur-
ther 21 genes were associated with the intergenic CpG
sites, identifying 49 genes as being differentially methyl-
ated. From the 49 genes, six genes showed differential
expression between the two tumour groups (SHH and
NR2E1 up-regulated in supratentorial astrocytomas; IRX2,
IRX1, HS3ST1 and LNX1 up-regulated in infratentorial
astrocytomas).
Discussion
We have found that pilocytic astrocytomas have a
hypomethylation signature that is independent of
tumour location and is absent in other types of paediat-
ric and adult gliomas and normal brain tissue. A subset
of the CpG sites is located at intragenic distal enhancer
regions of low CpG density, as identified in other malig-
nancies including medulloblastoma [17, 25, 54]. Further-
more, tissue-specific hypomethylation has been found at
distal regulatory regions of genes [16]. In a subset of
cancer-related genes that are associated with the dis-
tinctive signature in pilocytic astrocytomas, the affected
sites within the gene body showed greater correlation
with expression than the promoter region. Additionally,
we identified consensus AP-1 binding sites located at a
subset of the affected enhancers in pilocytic astrocyto-
mas and an up-regulation of AP-1 factors and target
genes in pilocytic astrocytomas compared to diffuse
astrocytomas and normal brain. A high proportion of
consensus AP-1 binding sites are reported to be located
within introns and intergenic regions, but their function
at these locations is not clear [29].
On further examination of the AP-1 target gene
CCND1, we identified up-regulation of CCND1a in both
pilocytic and diffuse astrocytomas compared to normal
brain control. Interestingly, a truncated transcript, CCND1b
has been shown to have oncogenic effects by transforming
NIH-3 T3 cells [34, 48] and is expressed in other cancers
[7]. CCND1b was expressed at higher levels in diffuse
astrocytomas compared to pilocytic astrocytomas. In the
low-grade astrocytomas, expression of CCND1b was not
Fig. 5 Expression of the AP-1 factors of the FOS and JUN families. Expression levels of AP-1 factors in normal brain controls (Foetal controls – diencephalon,
cerebellum, cerebral cortex; Adult controls – diencephalon, medulla, thalamus, cerebellum, cerebral cortex), diffuse astrocytomas and pilocytic astrocytomas.
The normalized expression values are log2 transformed. Affymetrix probe identifiers are shown (** p-value <0.01, * p-value <0.05, Mann-Whitney U-test)
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linked to SNP status at the splice site or DNA methylation
at this exon-intron boundary. High expression of the
oncogenic variant CCND1b may therefore be critical for
tumorigenesis in diffuse astrocytomas, and suggests that
defective splicing mechanisms may be present in these
tumours, as shown for other malignancies [38, 64].
Previous studies have shown that the cerebellum con-
tains more hypomethylated genes than the cerebral cor-
tex [26, 63]. Furthermore, DNA methylation patterns are
distinct in neuronal and non-neuronal cells, particularly
at enhancers and non-CpG sites [24]. The differences in
methylation patterns between brain regions could therefore,
Fig. 6 Analysis of AP-1 transcription factors and the AP-1 target gene CCND1. a Diagram showing the CCND1a transcript and the oncogenic splice
variant CCND1b. Alternative splicing at the exon4-intron 4 boundary leads to the CCND1b transcript that contains intron 4, with loss of
the post-transcriptional regulatory domain of exon 5 and 3’UTR. A stop codon (shown by the red cross) within the intron leads to truncated cyclin D1
protein. b Expression levels of CCND1a and CCND1b in controls, pilocytic and diffuse astrocytomas (Error bars show the standard deviation for the
average beta value for each tumour group). c Diagram of CCND, showing the location of SNP rs9344 (G870A) within a CpG at the splice site (CpG1)
and its neighbouring CpG site within the intron (CpG2). d CpG2, the closest intronic CpG site to the SNP, shows lower methylation levels in the
low-grade astrocytomas compared to normal brain controls (differential change >30 %; Mann-Whitney U-test- ** p-value <0.01, * p-value <0.05)
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at least in part, reflect variation in the neuronal:non-
neuronal cell ratio [12, 24]. These factors were reflected in
our findings when we performed comparisons between
the low-grade astrocytomas and normal brain from the
tumour location.
Comparison between the infratentorial and supraten-
torial pilocytic astrocytomas identified 49 genes as being
differentially methylated, of which 6 had been identified
previously [27]. Our findings may vary due to our supra-
tentorial tumours being located predominately in the
cerebral cortex, whereas the tumours in the previous
study came from varied supratentorial regions. A key
gene identified was NR2E1, which is important in the
regulation of neural stem cell expansion and gliomagenesis
[31, 68]. It is one of the genes reported to distinguish
infratentorial and supratentorial pilocytic astrocytomas
by their expression and/or DNA methylation profiles
[27, 46]. We also identified other homeobox genes
EMX2OS, MEIS1 and PBX3 that play a role in brain
development [2, 13, 44, 52, 58].
It remains to be established whether the differences
that we have observed arise from the specific genetic
changes in pilocytic and diffuse astrocytomas, or
whether the profiles reflect the methylation pattern in
the cell of origin [9, 36, 41]. Distinct outputs of the
MAPK pathway have been identified in melanoma and
other malignancies with BRAFV600E and receptor tyro-
sine kinase mutations. Additionally, genetic alterations
in mouse models of brain tumours often interfere with
normal differentiation processes and give rise to tumours
in a manner that is dependent on the tumour cell of
origin, as reviewed recently [53]. Pilocytic astrocytomas in
the optic pathway are believed to derive from radial glia
cells that are distinct from those giving rise to cerebellar
pilocytic astrocytomas [28, 57]. The identity of the tumour
precursor cells in non-optic pathway pilocytic astrocyto-
mas, however, remains elusive, even in mouse models [6].
The discovery of a unique methylation signature at a small
number of sites may facilitate the identification of tumour
precursor cells and in time enable the very earliest stages
of tumorigenesis to be better understood.
Conclusion
In summary, pilocytic astrocytomas contain a hypomethyla-
tion signature characterised by CpG sites which are located
predominantly in annotated enhancers. This signature is
specific to pilocytic astrocytomas and is not present in dif-
fuse astrocytomas, other brain tumours or normal brain tis-
sue. The AP-1 transcription factor complex, activated by the
MAPK pathway, is predicted to bind at a number of these
CpG sites, and FOS transcription factors are up-regulated in
pilocytic astrocytomas. Our findings highlight epigenetic dif-
ferences between pilocytic and diffuse astrocytoma, in
addition to the well-documented genomic alterations.
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torial pilocytic astrocytomas: PA7-PA17. Diffuse astrocytomas: DA1-DA10.
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Additional file 4: Table S3. Overview of comparisons performed
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FDR-corrected p-value <0.05) were identified by MethLAB analysis.
(PDF 104 kb)
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selected test tumours and controls. Expression analysis was performed
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<0.05), for 537 genes sorted by p-value. (XLSX 89 kb)
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and the data represented as heatmaps in Additional file 3: Figures S13-
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mas. Normal brain controls (1_Cerebellum [Lambert et al, Acta Neuro-
pathologica 126:291-301, 2013]; Cerebral cortex [Guintivano et al,
Epigenetics 8:290-302, 2013]); paediatric low-grade astrocytomas (2_valid-
ation tumour set 2; 3_[Lambert et al, Acta Neuropathologica 126:291-301,
2013]); adult low-grade astrocytomas (4_TCGA); paediatric and adult
high-grade astrocytomas (5_[Sturm et al, Cancer Cell 22:425-437, 2012]),
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946, 2013]; Ependymomas (7_GSE45353 [Mack et al, Nature 506:445-450,
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Additional file 10: Table S9. Comparison of pilocytic astrocytomas
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shown where δβ≥ 0.3 (Benjamini-Hochberg corrected p-value <0.05),
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genes associated with 315 differentially methylated sites in the test
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Additional file 12: Table S11. Normalised log2 expression values for
the genes associated with the 315 CpG sites. The δβ values between the
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expression for genes associated with 315 differentially methylated sites in
pilocytic and diffuse astrocytomas. Correlation coefficients are shown for
differentially methylated CpG sites that show a difference of ≥2-fold in
expression of the associated gene. Expression probes were only assessed
if they were located within the mRNA transcript. A) CpG sites located
within the promoter of the gene. B) CpG sites located within the gene
body, 3’UTR and intergenic regions. As the CpG is not within a promoter,
correlation was also calculated for a CpG site within the promoter (where
possible within the TSS200; brown panel). For each correlation p-values
and Benjamini-Hochberg corrected p-values are shown. The table is or-
dered by FDR-corrected p-values (sites with a p-value <0.05 are shown in
blue). Positive correlation is highlighted in yellow. Up-regulated genes in
diffuse astrocytomas are highlighted in green. When the expression
probe was located in an exon, the probe for the full transcript was used
for the correlation (indicated by the asterisk). (XLSX 85 kb)
Additional file 14: Table S13. Functions of genes which show a
significant correlation between DNA methylation and gene expression.
The majority of genes were hypomethylated in pilocytic astrocytomas
except the genes highlighted in bold, which were hypermethylated in
the pilocytic astrocytomas. (PDF 158 kb)
Additional file 15: Table S14. Predicted transcription factor binding
sites for the 315 differentially methylated signature in low-grade astrocy-
tomas. Table to show TRANSFAC predicted transcription factor binding
sites within a 200 bp region (100 bp either side of the CpG site detected
by the Illumina probe). Illumina annotation highlighted in grey and tran-
scription factor binding predictions plus sequence highlighted in blue.
List of the top predicted transcription factors and gene expression levels
of the top predicted transcription factors for the low-grade astrocytomas
are also shown. (XLSX 215 kb)
Additional file 16: Table S15. Differential expression of AP-1 target
genes in pilocytic astrocytomas compared to normal brain controls and
diffuse astrocytomas. 1_ List of published AP-1 target genes [Eferl and
Wagner, Nature Rev Cancer 3(11):853-868, 2003; Li et al, J Genet Genom-
ics 38(6):235-242, 2011] and predicted AP-1 target genes identified in the
315 differentially methylated sites. 2_ Table showing AP-1 target genes
that are differentially expressed in pilocytic astrocytomas compared to
normal brain controls and diffuse astrocytomas. For each gene, methyla-
tion and expression status, plus the normalized log2 transformed expres-
sion values for each sample are included. The data is ordered by
correlation with FOS expression (positive to negative correlation). The
colour coordination shows which genes were taken from the three lists.
(XLSX 101 kb)
Additional file 17: Table S16. The differentially methylated CpG sites
within de-regulated genes from the comparison between infratentorial
pilocytic astrocytomas and normal cerebellum controls. 1_ Features of 11,
671 probes that are significantly differentially methylated in infratentorial
pilocytic astrocytomas compared to published foetal and adult normal
cerebellum datasets (averaged beta values with a difference of δβ ≥ 0.3,
Benjamini-Hochberg corrected p-value <0.05 [Lambert et al, Acta Neuro-
pathologica 126:291-301, 2013]). 2_ Normalized log2 transformed expression
analysis identifies differentially expressed genes between infratentorial pilo-
cytic astrocytomas (n = 4) compared to normal cerebellum (n = 2, foetal and
adult cerebellum). Genes that show fold change >2 are highlighted. 3_ List
of genes that have differential methylation (δβ≥ 0.3) and differential gene
expression (fold change >2). (XLSX 4414 kb)
Additional file 18: Table S17. Ingenuity Pathway Analysis (IPA) of
genes associated with differentially methylated sites in infratentorial
pilocytic astrocytomas and normal cerebellum. IPA analysis of the top 20
significant biological and disease categories including their functional
annotation (p-value <0.05) identified for 161 genes that had ≤2 fold
change in gene expression and δβ ≥ 0.3, sorted by p-value. (XLSX 71 kb)
Additional file 19: Table S18. Differentially methylated CpG sites
identified between supratentorial pilocytic astrocytomas and cerebral
cortex controls. 1_ MethLAB analysis identified 90,249 CpG sites that are
significantly differentially methylated in supratentorial pilocytic
astrocytomas, diffuse astrocytomas, glial component of the cerebral
cortex, neuronal component of the cerebral cortex, adult cerebral cortex
and foetal cerebral cortex (Benjamini-Hochberg corrected p-value <0.05).
The adult cerebral cortex controls (including the glial and neuronal
components) were taken from [Guintivano et al, Epigenetics 8:290-302,
2013]. The number of differentially methylated sites (averaged beta
values with a difference of δβ ≥ 0.3, Benjamini-Hochberg corrected p-
value <0.05) identified in tumour and all controls was 382 CpG sites for
supratentorial pilocytic astrocytomas. 2_ CpG sites hypermethylated and
3_ hypomethylated in pilocytic astrocytomas compared to controls. 4_
Expression analysis for the genes that show differentially methylated CpG
sites. Highlighted genes show ≤ 2 fold change in expression compared
to controls. (XLSX 37842 kb)
Additional file 20: Table S19. Differentially methylated CpG sites
identified between diffuse astrocytomas and cerebral cortex controls. 1_
MethLAB analysis identified 90,249 CpG sites that are significantly
differentially methylated in supratentorial pilocytic astrocytomas, diffuse
astrocytomas, glial component of the cerebral cortex, neuronal
component of the cerebral cortex, adult cerebral cortex and foetal
cerebral cortex (Benjamini-Hochberg corrected p-value <0.05). The adult
cerebral cortex controls (including the glial and neuronal components)
were taken from [Guintivano et al, Epigenetics 8:290-302, 2013]. The
number of differentially methylated sites (averaged beta values with a
difference of δβ ≥ 0.3, Benjamini-Hochberg corrected p-value <0.05) iden-
tified in tumour and all controls was 58 CpG sites for the diffuse astrocy-
tomas. 2_ CpG sites hypermethylated and 3_ hypomethylated in diffuse
astrocytomas compared to controls. 4_ Expression analysis for the genes
that show differentially methylated CpG sites. Highlighted genes show ≤
2 fold change in expression compared to controls. (XLSX 37720 kb)
Additional file 21: Table S20. Differentially methylated CpG sites in
infratentorial pilocytic astrocytomas, supratentorial astrocytomas and
diffuse astrocytomas. 1_ MethLAB analysis identified 676 CpG sites that
are significantly differentially methylated in infratentorial pilocytic,
supratentorial pilocytic and diffuse astrocytomas (Benjamini-Hochberg
corrected p-value <0.05). 2_ The 72 differentially methylated CpG sites in
supratentorial and infratentorial pilocytic astrocytomas. 3_ The 393
differentially methylated CpG sites for infratentorial pilocytic astrocytomas
and diffuse astrocytomas (averaged beta values with δβ≥ 0.3, Benjamini-
Hochberg corrected p-value <0.05). 4_ Genes that show differentially
methylated CpG sites and expression between supratentorial and infra-
tentorial pilocytic astrocytomas (genes with fold change ≥ 2 highlighted
in grey). (XLSX 406 kb)
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